Insider Selling: Henry Schein (NASDAQ:HSIC) EVP Sells $478,740.00 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) EVP Mark Mlotek sold 5,925 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total transaction of $478,740.00. Following the sale, the executive vice president owned 80,554 shares in the company, valued at $6,508,763.20. This represents a 6.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Henry Schein Trading Down 3.2%

Shares of NASDAQ HSIC traded down $2.57 during trading hours on Friday, reaching $77.60. The stock had a trading volume of 1,724,801 shares, compared to its average volume of 1,443,707. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. The business’s fifty day moving average price is $78.17 and its two-hundred day moving average price is $72.50. The firm has a market cap of $8.90 billion, a price-to-earnings ratio of 23.73, a P/E/G ratio of 2.38 and a beta of 0.88. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $89.29.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same period in the prior year, the company posted $1.19 EPS. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Institutional Trading of Henry Schein

A number of institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC boosted its holdings in Henry Schein by 2.5% during the fourth quarter. Hsbc Holdings PLC now owns 123,550 shares of the company’s stock valued at $9,353,000 after acquiring an additional 3,014 shares during the period. Reflection Asset Management acquired a new position in Henry Schein during the 4th quarter valued at $516,000. Compound Planning Inc. acquired a new stake in Henry Schein in the 4th quarter worth $275,000. Corient Private Wealth LLC increased its holdings in shares of Henry Schein by 5.4% during the 4th quarter. Corient Private Wealth LLC now owns 37,019 shares of the company’s stock worth $2,798,000 after purchasing an additional 1,906 shares during the period. Finally, Mercer Global Advisors Inc. ADV raised its holdings in Henry Schein by 7.8% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company’s stock valued at $326,000 after acquiring an additional 312 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HSIC has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Wall Street Zen raised Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research report on Monday, February 23rd. Morgan Stanley upped their target price on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research note on Wednesday, February 25th. Finally, Leerink Partners increased their target price on shares of Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.